Waskyra
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Etuvetidigene autotemcel
- Used in
- Blood, clotting and anaemia
- Made by
- Fondazione Telethon ETS
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Waskyra is indicated for the treatment of patients aged 6 months and older with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom haematopoietic stem cell (HSC) transplantation is appropriate and no suitable human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is available.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Fondazione Telethon ETS |
|---|---|
| Active substance | Etuvetidigene autotemcel |
| Used in | Blood, clotting and anaemia |
| Classification | B06 · Blood, clotting and anaemia |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-01-09 |
| Last updated by the regulator | 2026-03-05 |
| EMA product number | EMEA/H/C/006525 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).